Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You in 2026?
Both GLP-1s drive real weight loss, but tirzepatide leads on efficacy while semaglutide has a longer safety record. Here's how to choose.
- glp-1
- semaglutide
- tirzepatide
- weight-loss
- comparison
If you're considering a GLP-1 medication for weight loss in 2026, two options dominate the conversation: semaglutide (brand names Wegovy and Ozempic) and tirzepatide (Zepbound and Mounjaro). Both are weekly injections. Both deliver clinically meaningful weight loss. The right one for you depends on your weight-loss goal, your tolerance for side effects, and what your insurance covers.
The short version
Tirzepatide produces more weight loss on average — about 21% at 72 weeks in the SURMOUNT-1 trial, versus 15% for semaglutide at 68 weeks in STEP-1. Semaglutide has been on the market longer, so its long-term safety data is stronger. Tirzepatide tends to cost slightly less out-of-pocket in 2026; both are covered by roughly the same proportion of US insurance plans when prescribed for BMI-based obesity.
Semaglutide vs Tirzepatide — 2026 head-to-head
| Attribute | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Avg weight loss | 14.9% at 68 weeks | 20.9% at 72 weeks |
| Brand cash price | $1,349/mo | $1,059/mo |
| Most common side effect | Nausea (44%) | Nausea (33%) |
| Years on market | 10+ (for T2D, 4+ for obesity) | 3+ |
How effective is each medication?
Head-to-head data from the SURMOUNT-5 trial (published 2025) showed tirzepatide led to 20.2% body-weight loss at 72 weeks compared with 13.7% for semaglutide — a difference of about 6.5 percentage points. In absolute terms, a 220-pound starting weight would lose ~44 lbs on tirzepatide versus ~30 lbs on semaglutide.
Who gets the best results with semaglutide?
Patients who prioritize a long safety track record, who have type 2 diabetes in addition to obesity, or whose insurance covers Wegovy but not Zepbound. Semaglutide has been studied in millions of patient-years. Anyone with a history of hypoglycemia is typically safer on semaglutide's single-agonist profile.
Who gets the best results with tirzepatide?
Patients with higher starting BMI who need greater weight loss, patients who didn't respond well to semaglutide, or those prioritizing the strongest efficacy. The dual GIP+GLP-1 mechanism appears to produce more consistent appetite suppression for many patients.
“In a head-to-head trial, tirzepatide outperformed semaglutide by about 6.5 percentage points of body-weight loss at 72 weeks.”
— SURMOUNT-5 trial, 2025
What are the side effects of each?
Both medications share the same side-effect profile because both act on the GLP-1 receptor. Nausea, constipation, diarrhea, and fatigue are the most common. About 80% of side effects occur during the first 8 weeks of dose titration and resolve as your body adjusts. Tirzepatide's larger appetite-suppression effect can cause slightly more early-phase nausea in some patients, but rates in the clinical trials were actually lower (33% vs 44%).
How to decide which one is right for you
Check your eligibility
Most telehealth clinics prescribe GLP-1 for a BMI of 30+ (obesity) or BMI 27+ with a weight-related condition like pre-diabetes, high blood pressure, or high cholesterol.
Check your insurance
Call your insurer. Ask if Wegovy (semaglutide) and/or Zepbound (tirzepatide) are on-formulary for weight management. Coverage varies widely by plan and by state.
Talk to a clinician
Share your medical history, current medications, and weight-loss goal. A licensed clinician can match you to the medication most likely to succeed for your profile.
Frequently asked questions
Is tirzepatide stronger than semaglutide?
Yes, in head-to-head clinical trials tirzepatide produced about 6 percentage points more body-weight loss than semaglutide at 72 weeks. Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide activates only GLP-1. This dual mechanism is the main reason for the efficacy difference. That said, 'stronger' is not always 'better' — individual response varies, and some patients tolerate semaglutide better.
Can I switch from semaglutide to tirzepatide?
Yes, many patients do. A typical switch involves stopping semaglutide on a Friday and starting tirzepatide the following Wednesday at its starter dose (2.5 mg), then titrating up on the standard tirzepatide schedule. Always coordinate the switch with a licensed clinician — dosing, timing, and side-effect management matter for a smooth transition.
Which medication has fewer side effects?
In clinical trials, tirzepatide actually had slightly lower rates of nausea (33% vs 44%) and discontinuation than semaglutide. However, both medications share the same side-effect profile — nausea, constipation, diarrhea, fatigue — and most side effects occur during the first 8 weeks of dose titration. Individual response varies; the 'best-tolerated' medication is the one your body handles best, which you only know by trying it under clinical supervision.
Not sure which is right for you?
Take our free 2-minute evaluation. A licensed clinician will review your profile and recommend the right GLP-1 for your goals.